ALEC - Alector Inc

ALEC - Alector Inc

https://www.alector.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Lifecore Biomedical ( LFCR ) Soars 10.8%: Is Further Upside Left in the Stock?

Zacks Commentary • 3 days, 2 hours ago

Lifecore Biomedical (LFCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Alector to Participate in Upcoming Healthcare Conferences - Alector ( NASDAQ:ALEC )

Benzinga • 2 weeks, 4 days ago • score: 0.16

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Alector, Inc. ALEC, a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following ...

After Golden Cross, Alector ( ALEC ) 's Technical Outlook is Bright

Zacks Commentary • 3 weeks, 3 days ago • score: 0.54

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

Alector ( ALEC ) Reports Q2 Loss, Tops Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.07

Alector (ALEC) delivered earnings and revenue surprises of +33.33% and +177.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

This Texas Instruments Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - MARA Holdings ( NASDAQ:MARA ) , Alector ( NASDAQ:ALEC )

Benzinga • 1 month, 2 weeks ago • score: 0.44

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Matthew Boss upgraded the rating for NIKE, Inc.

Alector Provides Executive Leadership Update - Alector ( NASDAQ:ALEC )

Benzinga • 3 months ago • score: 0.38

-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 ( GLOBE NEWSWIRE ) -- Alector, Inc.

Alector Provides Executive Leadership Update

GlobeNewswire • 3 months ago • score: 0.34

-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 ( GLOBE NEWSWIRE ) -- Alector, Inc. ( Nasdaq: ALEC ) , a late-stage clinical biotechnology company focused on developing ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. The company is headquartered in South San Francisco, California.

52W High

$6.37

52W Low

$0.87

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.00

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

526.32

EV/EBITDA (<8 favorable)

-8.40

EV/Revenue (<3 favorable)

0.45

P/S (TTM) (<3 favorable)

3.76

P/B (<3 favorable)

4.28

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

10.37%

Institutions (25–75% balanced)

77.10%

Shares Outstanding

101,212,000

Float

84,721,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

81,130,000

Gross Profit (TTM)

-74,581,000

EPS (TTM)

-1.16

Profit Margin (>10% good)

-1.42%

Operating Margin (TTM) (higher better)

-4.34%

ROE (TTM) (>15% strong)

-1.04%

EPS YoY (Quarterly) (>10% good)

-0.86

Revenue YoY (Quarterly) (>8% good)

-0.48

Momentum

Bearish momentum

Value

0.3008

Previous

0.3041

Trend

Falling

Signal Cross

No cross

As of

Sep. 11, 2025